Rheumatoid arthritis market to get heated

Published: 2011-08-16 06:56:00

Updated: 2011-08-16 06:56:00

Competition is about to heat up in the domestic rheumatoid arthritis market as Green Cross Corp. will also join the market by launching its newly developed natural drug “Shinbaro” from next month.

A 12-week study over Pfizer’s Cerebrex indicated that Shinbaro is not inferior to the control dru...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK